glp-1 obesity drug updates CMS Issues Coverage Guidance on Anti-Obesity Drugs GLP-1 Targeted Peptide Weight Loss

The researcher believes that it may be related to the patients habit of excessive intake (44)

Sulphonylureas and insulin usage, for instance, can elevate the possibility of low blood glucose, while gain in weight is commonly observed with insulin, sulphonylureas, and thiazolidinediones

Endoscopic sleeve gastroplasty, for instance, is a relatively new procedure that does not require a surgeon to make incisions in the skin

doi: 10.1111/dom.14280 [DOI] [PMC free article] [PubMed] [Google Scholar] 183.Ushakumari DS, Sladen RN

The report found GLP-1 adoption has continued to increase across the United States, rising to 13.1% of US adults in June 2026 from 12% in November 2025

Katz also stated that they are not recommending anyone stop using GLP-1 drugs or not use these drugs if theyre recommended by their doctor